Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cesar Ochoa-Lubinoff

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Neurologic Clinics|April 8, 2023
Autism in WomenCesar Ochoa-Lubinoff, Bridget A Makol, Emily F Dillon
International Journal of Speech-Language Pathology|July 3, 2019
Screening school-age children for developmental language disorder in primary careKerry Danahy Ebert, Cesar Ochoa-Lubinoff, Melissa P Holmes
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|April 11, 2023
Health-related quality of life and medication use among individuals with Angelman syndromeNasreen Khan, Raquel Cabo, Rebecca D Burdine, et al.
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|September 9, 2023
An adapted clinical global Impression of improvement for use in Angelman syndrome: Validation analyses utilizing data from the NEPTUNE studyPamela Ventola, Judith Jaeger, Christopher J Keary, et al.
American Journal of Medical Genetics. Part A|September 9, 2017
Pharmacological interventions to improve cognition and adaptive functioning in Down syndrome: Strides to dateSarah J Hart, Jeannie Visootsak, Paul Tamburri, et al.
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|August 28, 2023
Gaboxadol in angelman syndrome: A double-blind, parallel-group, randomized placebo-controlled phase 3 studyChristopher Keary, Lynne M Bird, Marie-Claire de Wit, et al.
Neurology|January 14, 2021
The STARS Phase 2 Study: A Randomized Controlled Trial of Gaboxadol in Angelman SyndromeLynne M Bird, Cesar Ochoa-Lubinoff, Wen-Hann Tan, et al.
Journal of Neurodevelopmental Disorders|July 26, 2023
Enabling endpoint development for interventional clinical trials in individuals with Angelman syndrome: a prospective, longitudinal, observational clinical study (FREESIAS)Jorrit Tjeertes, Carlos A Bacino, Terry Jo Bichell, et al.
Journal of Clinical Medicine|April 30, 2021
Cross-Sectional Exploration of Plasma Biomarkers of Alzheimer's Disease in Down Syndrome: Early Data from the Longitudinal Investigation for Enhancing Down Syndrome Research (LIFE-DSR) StudyJames A Hendrix, David C Airey, Angela Britton, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Neurologic Clinics|April 8, 2023
Autism in WomenCesar Ochoa-Lubinoff, Bridget A Makol, Emily F Dillon
International Journal of Speech-Language Pathology|July 3, 2019
Screening school-age children for developmental language disorder in primary careKerry Danahy Ebert, Cesar Ochoa-Lubinoff, Melissa P Holmes
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|April 11, 2023
Health-related quality of life and medication use among individuals with Angelman syndromeNasreen Khan, Raquel Cabo, Rebecca D Burdine, et al.
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|September 9, 2023
An adapted clinical global Impression of improvement for use in Angelman syndrome: Validation analyses utilizing data from the NEPTUNE studyPamela Ventola, Judith Jaeger, Christopher J Keary, et al.
American Journal of Medical Genetics. Part A|September 9, 2017
Pharmacological interventions to improve cognition and adaptive functioning in Down syndrome: Strides to dateSarah J Hart, Jeannie Visootsak, Paul Tamburri, et al.
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|August 28, 2023
Gaboxadol in angelman syndrome: A double-blind, parallel-group, randomized placebo-controlled phase 3 studyChristopher Keary, Lynne M Bird, Marie-Claire de Wit, et al.
Neurology|January 14, 2021
The STARS Phase 2 Study: A Randomized Controlled Trial of Gaboxadol in Angelman SyndromeLynne M Bird, Cesar Ochoa-Lubinoff, Wen-Hann Tan, et al.
Journal of Neurodevelopmental Disorders|July 26, 2023
Enabling endpoint development for interventional clinical trials in individuals with Angelman syndrome: a prospective, longitudinal, observational clinical study (FREESIAS)Jorrit Tjeertes, Carlos A Bacino, Terry Jo Bichell, et al.
Journal of Clinical Medicine|April 30, 2021
Cross-Sectional Exploration of Plasma Biomarkers of Alzheimer's Disease in Down Syndrome: Early Data from the Longitudinal Investigation for Enhancing Down Syndrome Research (LIFE-DSR) StudyJames A Hendrix, David C Airey, Angela Britton, et al.
Pageof 1